Investigational drug · Phase 2
Rosnilimab
Also called: ANB030
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis, Ulcerative Colitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Rosnilimab"
First trial start
2023
Aug 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rosnilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
- Ulcerative Colitis
Approved drugs for the same conditions: Rheumatoid arthritis · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Rosnilimab" as an intervention, largest first.
- A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Pivotal-lookingActive, not recruiting
AnaptysBio, Inc.Industry
NCT06041269 · 420 participants (planned) · Start Aug 31, 2023 · Primary completion Nov 29, 2024
Drug: Rosnilimab; Placebo · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Glendale, Arizona; Phoenix, Arizona · 92 sites in all
- A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)Pivotal-lookingActive, not recruiting
AnaptysBio, Inc.Industry
NCT06127043 · 132 participants (planned) · Start Dec 4, 2023 · Primary completion Jan 2026
Drug: Rosnilimab; Placebo · For: Ulcerative Colitis
Sites: Phoenix, Arizona; Garden Grove, California; Lancaster, California · 100 sites in all
AnaptysBio, Inc.Industry
NCT05205070 · 45 participants (planned) · Start Dec 22, 2021 · Primary completion Jan 19, 2023
Drug: Rosnilimab; Placebo · For: Alopecia Areata
Sites: Birmingham, Alabama; Encinitas, California; Northridge, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Breaking and Making Tolerance: The PD-1/PD-L1 Axis in Lupus Nephritis.
Li Y, Fang X, Gao X, et al. · Immunol Invest 2026
- Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission.
Afshari A, Khorramdelazad H, Abbasifard M · Int Immunopharmacol 2025
- Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Neurath MF, Sands BE, Rieder F · Gut 2024
- Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA, Tosti A · Expert Opin Emerg Drugs 2022
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.